Abstract
AbstractA series of novel 6‐amino‐5‐salicylidene uracils (1–19) were efficiently synthesized from the condensation reaction of 5,6‐diamino‐1,3‐dimethyluracil with substituted salicylaldehydes. The structural characterization of the compounds was performed with spectroscopic methods and elemental analysis. All compounds were evaluated for their in vitro cytotoxic activity against PC‐3 (human prostate adenocarcinoma), A549 (human alveolar adenocarcinoma) and SHSY‐5Y (human neuroblastoma) cancer cell lines. 3,5‐di‐tert‐Butylsalicylaldehyde derived salicylideneuracil (6ASU‐8) showed promising cytotoxic activity against PC‐3 cells with an IC50 value of 1.53±1.01 μM, compared to doxorubicin, which had an IC50 value of 3.77±1.34 μM. 6ASU‐8 induced cell cycle arrest at the G2/M phase and promoted apoptosis in PC‐3 cells (p<0.05*). Molecular docking results supported the experimental data, indicating that 6ASU‐8 is more effective than doxorubicin. Additionally, in silico ADME analysis revealed that 6ASU‐8 possesses acceptable predictive physicochemical properties.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
